Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1997-04-07
1999-03-30
Saunders, David
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241451, 424810, 514 2, 53038823, 5303892, A61K 39395, A01N 3718, C07K 1624, C07K 1628
Patent
active
058885102
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a chronic rheumatoid arthritis therapy or synovial cell growth inhibitor comprising an interleukin-6 antagonist as an effective component.
BACKGROUND ART
Chronic rheumatoid arthritis is a systemic chronic inflammatory disease in which abnormal growth of connective tissue, including synovial tissue, occurs in the joints (Melnyk et al., Arthritis Rheum. 33: 493-500, 1990). The joints of chronic rheumatoid arthritis patients have been shown to have marked growth of synovial cells, formation of a multilayer structure due to abnormal growth of the synovial cells (pannus formation), invasion of the synovial cells into cartilage tissue and bone tissue, vascularization toward the synovial tissue, and infiltration of inflammatory cells such as lymphocytes and macrophages. Mechanisms of onset of chronic rheumatoid arthritis have been reported to be based on such factors as heredity, bacterial infection and the contribution of various cytokines and growth factors, but the overall mechanism of onset has remained unclear.
In recent years, cytokines and growth factors including interleukin-1 (IL-1), interleukin-8 (IL-8), tumor necrosis factor .alpha. (TNF.alpha.), transforming growth factor .beta. (TGF.beta.), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) have been detected in the synovial membrane and synovial fluid of chronic rheumatoid arthritis patients (Nouri et al., Clin. Exp. Immunol. 55:295-302, 1984; Thornton et al., Clin. Exp. Immunol. 86:79-86, 1991; Saxne, et al., Arthritis Rheum. 31:1041-1045, 1988; Seitz et al., J. Clin. Invest. 87:463-469, 1991; Lafyatis et al., J. Immunol. 143:1142-1148, 1989; Melnyk et al., Arthritis Rheum. 33:493-500, 1990).
It is believed that IL-1, TNFA and PDGF are particularly powerful synovial cell growth factors (Thornton et al., Clin. Exp. Immunol. 86:79-86, 1991; Lafyatis et al., J. Immunol. 143:1142-1148, 1989; Gitter et al., Immunology 66:196-200, 1989). It has also been suggested that stimulation by IL-1 and TNF results in production of interleukin-6 (IL-6) by synovial cells (Ito et al., Arthritis Rheum. 35:1197-1201, 1992).
IL-6 is a cytokine also known as B cell-stimulating factor 2 or interferon .beta.2. IL-6 was discovered as a differentiation factor contributing to activation of B lymphoid cells (Hirano, T. et al., Nature 324, 73-76, 1986), and was later found to be a multifunction cytokine which influences the functioning of a variety of different cell types (Akira, S. et al., Adv. in Immunology 54, 1-78, 1993). Two functionally different membrane molecules are necessary for the induction of IL-6 activities. One of those is IL-6 receptor (IL-6R), an approximately 80 KD molecular weight, which binds specifically to IL-6.
IL-6R exists in a membrane-binding form which is expressed on the cell membrane and penetrates the cell membrane, as well as in the form of soluble IL-6R (sIL-6R) which consists mainly of the extracellular domain. Another protein is gp130 with a molecular weight of approximately 130 KD, which is non-ligand-binding but rather functions to mediate signal transduction. IL-6 and IL-6R form the complex IL-6/IL-6R which in turn binds with another membrane protein gp130, to induce the biological activity of IL-6 to the cell (Taga et al., J. Exp. Med. 196:967, 1987).
It has been reported that the serum or synovial fluid of chronic rheumatoid arthritis patients contains excessive amounts of interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) (Houssiau et al., Arthritis Rheum. 31:784-788, 1988; Hirano et al., Eur. J. Immunol. 18:1797-1801, 1988; Yoshioka et al., Japn. J. Rheumatol. in press), and since similar results have also been obtained in rheumatoid arthritis animal models (Takai et al., Arthritis Rheum. 32:594-600, 1989; Leisten et al. Clin. Immunol. Immunopathol. 56: 108-115, 1990), it has been suggested that IL-6 is somehow involved in chronic rheumatoid arthritis.
However, Japanese Unexamined Patent Publication No. 4-89433 discloses that peptides which strongly promote I
REFERENCES:
patent: 5210075 (1993-05-01), Scholz et al.
patent: 5559012 (1996-09-01), Brailly et al.
patent: 5591827 (1997-01-01), Brakenhoff et al.
Sipe, JD et al. Mediators of Inflammation. 3(4): 243-256, Apr. 1994.
Harigai et al., Rheumatoid Adherent Synovial Cells Produce B Cell Differentiation Factor Activity Neutralizable By Antibody to B Cell Stimulatory Factor-2/Interleukin 6, The Journal of Rhematology,pp. 1616-1622, (1988).
Yasukawa et al., A Research on Inhibitor of Interleukin-6, Journal of TOSOH Research, vol. 35(2):77-91, (1991).
Matsuda et al., "Establishment of An Interleukin 6 (IL-6)/B Cell Stimulatory Factor 2-dependent Cell Line And Preparation Of Anti-IL 6 Monoclonal Antibodies", Eur. J. Immunol., vol. 18:951-956, (1988).
Hirata et al., "Characterization Of IL-6 Receptor Expression By Monoclonal And Polyclonal Antibodies", The Journal of Immunology, vol. 143:2900-2906, (1989).
Hirano, et al. "Excessive Production of Interleukin 6/B Cell Stimulatory Factor-2 in Rheumatoid Arthritis," Eur. J. Immunol. 18:1797-1801 (1988).
Houssiau, et al. "Interleukin-6 in Synolvial fluid and Serum of Patients with Rheumatoid Arthritis and Other Inflammatory Arthritis," Arthritis and Rheumatism 31: 784-788 (1988).
Waage, et al. "Interleukin-6 in Synovial Fluid From Patients With Arthritis," Clinical Immunology and Immunopathology 50: 394-398 (1989).
Bhardwaj, et al. "IL-6/IFN-.beta..sub.2 In Synovial Effusions Of Patients With Rheumatoid Arthritis and Other Arthritides," J. of Immunology 143: 2153-2159 (1989).
Aderka, et al. "IL-6 Inhibits Lipopolysaccharide-induced Tumor Necrosis Factor Production In Cultured Human Monocytes U937 Cells, And In Mice," J. of Immunology 143: 3517-3523 (1989).
Schindler, et al. "Correlations and Interactions In The Production of Interleukin-6 (IL-6), IL-1, and Tumor Necrosis Factor (TNF) in Human Blood Mononuclear Cells: IL-6 Suppresses IL-1 and TNF," Blood 75: 40-47 (1990).
Yasukawa, et al. "A Research On Inhibitor Of Interleukin-6, and partial translation thereof," J. of TOSOH Research 35: 77-91 (1991).
Mihara, et al. "Interleukin 6 Inhibits Delayed-Type Hypersensitivity and The Development Of Adjuvant Arthritis," Eur. J. Immunol. 21: 2327-2331 (1991).
Heremans, et al. "Protective Effect Of Anti-Interleukin-6 Antibody Against Endotoxin, Associated With Paradoxically Increased IL-6 Levels," Eur. J. Immunol. 22: 2395-2401 (1992).
Wendling, et al. "Treatment of Severe Rheumatoid Arthritis By Anti-Interleukin 6 Monoclonal Antibody," J. of Rheumatology 20: 259-262 (1993).
Sack, et al. "Interleukin-6 In Synovial Fluid Is Closely Associated With Chronic Synovitis In Rheumatoid Arthritis," Rheumatol. Int. 13: 45-51 (1993).
Madhok, et al. "Serum Interleukin-6 Levels In Rheumatoid Arthritis: Correlations With Clinical And Laboroatory Indices Of Disease Activity," Annals of the Rheumatic Diseases 52: 232-234 (1993).
Tilg, et al. "Interleukin-6 (IL-6) as an Anti-inflammaotry Cytokine: Induction Of Circulating IL-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor p55," Blood 83: 113-118 (1994).
Punzi et al. "Interrelationship between synovial fluid interleukin (IL)-6, IL-1.beta. and disease activity indices in rheumatoid arthritis," Rheumatol. Int. (1994) 14, 83-84.
Monier et al. "Growth factor activity of IL-6 in the Synovial Fluid of Patients with Rheumatoid Arthritis," Clinical and Experimental Rheumatology (1994) 12, 595-602.
Fukamachi et al. "Interleukin-6 Receptor (IL-6R) Dynamics in Patients with Rheumatoid Arthritis", Japanese Journal of Inflamation (1994) 14, 489-497.
Wijdenes et al. "Interleukin-6 Antibodies in Rheumatoid Arthritis", Journal of Interferon Research (1994) 14, 297-298.
Tanabe, M. et al. "Remarkable Elevation of Interleukin 6 and Interleukin 8 Levels in the Bone Marrow Serum of Patients with Rheumatoid Arthritis", The Journal of Rheumatology (1994) 21, 830-835.
Mihara et al. "Interleukin-6 (IL-6) Induces the Proliferation of Synovial Fibroblastic Cells in The Presence of Soluble IL-6 Receptor", Bri
Kishimoto Tadamitsu
Mihara Masahiko
Moriya Yoichiro
Ohsugi Yoshiyuki
Chugai Seiyaku Kabushiki Kaisha
Saunders David
Tadamitsu Kishimoto
VanderVegt F. Pierre
LandOfFree
Chronic rheumatoid arthritis therapy containing IL-6 antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chronic rheumatoid arthritis therapy containing IL-6 antagonist , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chronic rheumatoid arthritis therapy containing IL-6 antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1211812